Clinical Trial: Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07871409) titled 'Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight' on Oct. 07.

Brief Summary: The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

Study Start Date: Oct. 28

Study Type: INTERVENTIONAL

Condition: Obesity Overweight

Intervention: DRUG: Maridebart cafraglutide

Administered subcutaneously.

DEVICE: Autoinjector

The AI will be used by participants to self-administer SC doses of maridebart cafraglutide.

Recruitment Status: NOT_YET_RECRUITING

Sponsor:...